UK life sciences company Isomorphic Labs has announced it has raised $2.1 billion to scale its AI drug design engine. The company raised the capital in a Series B financing round, which Isomorphic Labs says will accelerate the company's evolution from pioneering novel AI models to applying them at scale. The financing round was led by […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!